Allogeneic hematopoietic stem cell transplantation for pediatric acute leukemia harboring the PICALM-MLLT10 fusion in two cases.
10.7499/j.issn.1008-8830.2503092
- Author:
Yu CHEN
1
;
Yong-Bing ZHU
1
;
Jia-Si ZHANG
1
;
Ai ZHANG
1
;
Ya-Qin WANG
1
;
Qun HU
1
;
Ai-Guo LIU
1
Author Information
1. Department of Pediatric Hematology/Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Publication Type:English Abstract
- Keywords:
Acute leukemia;
Child;
Hematopoietic stem cell transplantation;
PICALM-MLLT10
- MeSH:
Humans;
Hematopoietic Stem Cell Transplantation;
Male;
Female;
Child, Preschool;
Transplantation, Homologous;
Child;
Leukemia, Myeloid, Acute/genetics*;
Oncogene Proteins, Fusion/genetics*
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(11):1414-1419
- CountryChina
- Language:Chinese
-
Abstract:
A retrospective analysis was conducted on the clinical course of two children with PICALM-MLLT10-positive acute leukemia treated at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, between July 2021 and July 2023. The patients were diagnosed with acute T-lymphoblastic leukemia with central nervous system involvement and high-risk acute myeloid leukemia, respectively. Both achieved bone marrow complete remission after conventional chemotherapy combined with venetoclax. Following conversion to molecular negativity, they underwent sequential allogeneic hematopoietic stem cell transplantation. At the latest follow-up, both patients were alive and in good clinical condition. These observations suggest that proceeding to hematopoietic stem cell transplantation after venetoclax-based chemotherapy may improve the long-term survival of children with PICALM-MLLT10-positive leukemia.
